SCHEMBL5011982

SCHEMBL5011982

Cc1ccc(-n2nc(C)cc2Nc2ccccc2C(=O)Nc2ccncc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 2/20 0.56
MAPT P10636 1/20 0.54
GAA P10253 3/20 0.49
TSHR P16473 1/20 0.48
KCNJ6 P48051 1/20 0.48
KCNJ5 P48544 1/20 0.48
KCNJ3 P48549 1/20 0.48
TYK2 P29597 1/20 0.48
POLB P06746 1/20 0.47
NTRK1 P04629 2/20 0.46
RIPK1 Q13546 1/20 0.46
MAPK1 P28482 2/20 0.46
IRAK4 Q9NWZ3 2/20 0.46
LMNA P02545 1/20 0.46
KMT2A Q03164 1/20 0.45
HPGD P15428 1/20 0.45
MAPK13 O15264 1/20 0.45
MAPK12 P53778 1/20 0.45
MAPK11 Q15759 1/20 0.45
MAPK14 Q16539 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5010630 0.89 GFER (0.53) GFERMAPTGAATSHRKCNJ6
SCHEMBL5010571 0.86 GFER (0.59) GFERMAPTGAATSHRKCNJ6
SCHEMBL5012030 0.84 GFER (0.57) GFERMAPTGAAKCNJ6KCNJ5
SCHEMBL5005260 0.82 GFER (0.62) GFERMAPTGAANTRK1MAPK1
SCHEMBL6343958 0.81 GFER (0.73) GFERMAPTGAATSHRKCNJ6
SCHEMBL5008476 0.81 GFER (0.64) GFERMAPTGAATSHRKCNJ6
SCHEMBL5008426 0.80 GFER (0.66) GFERMAPTGAATSHRKCNJ6
SCHEMBL5008346 0.76 GFER (0.80) GFERMAPTGAATSHRKCNJ6
SCHEMBL23203458 0.74 KCNJ6 (0.85) MAPTGAATSHRKCNJ6KCNJ5
SCHEMBL1819140 0.73 GFER (0.71) GFERMAPTGAATSHRKCNJ6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2008-03-13 US disclosed
US-7265144-B2 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes IAPP, GLP1R, GPR119 GFER 1604/4885MAPT 2420/4885GAA 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.